Clinical trial NCT03043729: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
Official title: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rectal Cancer
Rectosigmoid Cancer
Keywords: neoadjuvant
MRI-defined T3
mFOLFOX6
Aflibercept
Lead sponsor: AIO-Studien-gGmbH
Sponsor class: OTHER
Collaborators: name: Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt
name: Sanofi
First posted: 2017-02-06
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI will receive 6 cycles of neoadjuvant treatment with mFOLFOX6 (Arm A) vs. mFOLFOX6 + aflibercept (Arm B) followed by surgery.

Detailed description: Patients with locally advanced rectal cancer are generally recommended to receive preoperative radiotherapy or radiochemotherapy. The advantage of combined-modality therapy in rectal cancer is that it has reduced local pelvic recurrence - a dreaded and morbid event - to rates of about 10%. There is good quality evidence that preoperative radiotherapy reduces local recurrence but there is little if any impact on overall survival. One strategy to reduce the distant recurrence rate, and thereby increase the cure rate, would be to introduce systemic treatment earlier to prevent dissemination of micrometastases. The present trial is designed to compare two neoadjuvant chemotherapy regimens in patients with non-metastatic T3 CRM-negative rectal cancers using quality-controlled MRI of the pelvis as a main inclusion criterion. This strategy is believed to reduce acute and long-term toxicity caused by preoperative radiotherapy and to administer effective systemic chemotherapy early in the course of disease as neoadjuvant chemotherapy.

Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18 years on day of signing informed consent
2. Signed and dated informed consent, and willing and able to comply with protocol requirements
3. WHO/ECOG Performance Status (PS) 0-1
4. Diagnosis of rectal adenocarcinoma
5. Candidate for sphincter-sparing surgical resection prior to neoadjuvant therapy according to the primary surgeon, i.e. no patient will be included for whom surgeon indicates need for abdomino-perineal resection (APR) at baseline.
6. Clinical staging is based on the combination of the following assessments:

   * Physical examination by the primary surgeon
   * CT scan of the chest/abdomen
   * Pelvic MRI
   * Rigid rectoscopy / endoscopic ultrasound (ERUS).
   * Both examinations (i.e. MRI and ERUS) are mandatory.
7. The tumor has to fulfill the following criteria:

   * No symptomatic bowel obstruction
   * Locally advanced rectal and rectosigmoid cancer, i.e. lower border of tumor \> 5 cm and \< 16 cm from anal verge as determined by rigid rectoscopy
   * MRI criteria:

     1. Lower border of tumor below a line defined by promontorium and symphysis, regardless of the criterion "\< 16 cm from anal verge as determined by rigid rectoscopy".
     2. No evidence that tumor is adjacent to (defined as within 2 mm of) the mesorectal fascia on MRI (i.e. CRM \> 2 mm)
     3. Only T3-tumors are included, i.e infiltration into perirectal fat \< 10 mm provided CRM \> 2 mm
     4. Note: MRI criteria are used for the definition of T3 tumor (i.e. exclusion of T2 and T4 situation).
8. Hematological status:

   * Neutrophils (ANC) ≥ 2 x 10\^9/L
   * Platelets ≥ 100 x 10\^9/L
   * Hemoglobin ≥ 9 g/dL (previous transfusion of packed blood cells allowed)
9. Adequate renal function:

   * Serum creatinine level ≤ 1.5 x upper limit normal (ULN) or ≤ 1.5 mg/dl
   * Creatinine clearance ≥ 30 ml/min
10. Adequate liver function:

    * Serum bilirubin ≤ 1.5 x upper limit normal (ULN)
    * Alkaline phosphatase \< 3 x ULN
    * AST and ALT \< 3 x ULN
11. Proteinuria \< 2+ (dipstick urinalysis) or ≤ 1 g/24hour or ≤ 500mg/dl
12. Regular follow-up feasible
13. For female patients of childbearing potential, negative pregnancy test within 1 week (7 Days) prior of starting study treatment
14. Female patients of childbearing potential (i.e. did not undergo surgical sterilization - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and is not post-menopausal for at least 24 consecutive months) must commit to using high effective and appropriate methods of contraception until at least 6 months after the end of study treatment such as combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner, sexual abstinence. If an oral contraception is used, a barrier method of contraception (e.g. male condom, female condom, cervical cap, diaphragm, contraceptive sponge) has to be applied additionally
15. Fertile male patients with a partner of childbearing potential must commit to using high effective and appropriate methods of contraception (details see above) until at least 9 months after the end of study treatment.

Exclusion Criteria:

1. Distant metastases (CT scans of thorax and abdomen are mandatory)
2. cT2 and cT4 tumors (defined by MRI criteria)
3. Exclusion of potentially compromised CRM as defined by MRI criteria (i.e. \> 2 mm distance from CRM)
4. Prior antineoplastic therapy for rectal cancer
5. History or evidence upon physical examination of CNS metastasis
6. Uncontrolled hypercalcemia
7. Pre-existing permanent neuropathy (NCI-CTCAE grade ≥ 2)
8. Uncontrolled hypertension (defined as systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg), or history of hypertensive crisis, or hypertensive encephalopathy
9. Concomitant protocol unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy, radiotherapy)
10. Treatment with any other investigational medicinal product within 28 days prior to study entry
11. Known dihydropyrimidine dehydrogenase (DPD) deficiency
12. Treatment with CYP3A4 inducers unless discontinued \> 7 Days prior to randomization
13. Any of the following in 3 months prior to inclusion:

    * Grade 3-4 gastrointestinal bleeding
    * Treatment resistant peptic ulcer disease
    * Erosive esophagitis or gastritis
    * Infectious or inflammatory bowel disease
    * Diverticulitis
14. Any active infection within 2 weeks prior to study inclusion
15. Vaccination with a live, attenuated vaccine within 4 weeks prior to the first administration of the study medication
16. Other concomitant or previous malignancy, except:

    * Adequately treated in-situ carcinoma of the uterine cervix
    * Basal or squamous cell carcinoma of the skin
    * Cancer in complete remission for \> 5 years
17. Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days prior to study entry
18. Pregnant or breastfeeding women
19. Patients with known allergy to any constituent to study drugs
20. History of myocardial infarction and/or stroke within 6 months prior to randomization, NYHA class III and IV congestive heart failure
21. Severe renal insufficiency (creatinin clearance \< 30 ml/min)
22. Bowel obstruction
23. Contra-indication to the assessment by MRI
24. Involvement in the planning and/or conduct of the study (applies to both Sanofi staff and/or staff of Sponsor and study site)
25. Patient who might be dependent on the sponsor, site or the investigator
26. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG
27. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts \[§ 40 Abs. 1 S. 3 Nr. 3a AMG\].

Primary outcomes:
measure: Pathologic complete response (pCR)
timeFrame: 20 weeks
Secondary outcomes:
measure: Dose intensities of study medication
timeFrame: 12 weeks
measure: Type, incidence and severity of AEs, SAEs
timeFrame: 20 weeks
measure: Dose reduction or discontinuation of study drug due to adverse events
timeFrame: 20 weeks
measure: Rate of treatment discontinuation due to toxicity
timeFrame: 20 weeks
measure: Type, incidence and severity of laboratory abnormalities
timeFrame: 20 weeks
measure: Rate of patients with R0-wide resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)
timeFrame: 20 weeks
measure: Rate of patients with R0-narrow resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)
timeFrame: 20 weeks
measure: Rate of patients with R1 resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)
timeFrame: 20 weeks
measure: Rate of patients with locoregional R2 resection (according to CRM definitions in S3 guideline-Version 1.1 August 2014)
timeFrame: 20 weeks
measure: Rate of number of patients with R0-wide, R0-narrow (according to CRM definitions in S3 guideline-Version 1.1 August 2014), R1 and locoregional R2 resection
timeFrame: 20 weeks
measure: Disease-free survival (DFS)
timeFrame: 44 weeks
measure: Relapse-free survival (RFS) in resected patients
timeFrame: 44 weeks
measure: Overall survival (OS) rate
timeFrame: 44 weeks
measure: Downstaging ability in resected patients using a standardized regression grading (Dworak regression grading)
timeFrame: 20 weeks
measure: Downsizing ability in resected patients using a standardized regression grading (Dworak regression grading)
timeFrame: 20 weeks
measure: Type, incidence and severity of perioperative medical events within 28 days after surgery are assessed. Perioperative morbidity is categorized according to the Clavien-Dindo-Classification
timeFrame: 20 weeks
measure: Mortality after surgery
timeFrame: 20 weeks
measure: Vital signs
timeFrame: 20 weeks
measure: Physical examination
timeFrame: 20 weeks
measure: ECOG
timeFrame: 20 weeks
Other outcomes:
Locations:
city: Mannheim
country: Germany
facility: Tagestherapiezentrum am ITM & III. Med. Klinik
Study officials:
affiliation: Tagestherapiezentrum am ITM & III. Med. Klinik, Universitätsmedizin Mannheim
name: Ralf-Dieter Hofheinz, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: